Mimedx Group, Inc. (MDXG) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
the bull case· 2
226
managers reporting a position in thirteen f filings
13fJun 30 '26+8.82%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 3
0.11%
of State Street SPDR S&P Biotech ETF's assets the largest fund weight on file
n-portJun 30 '265 of 23
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '2619
managers whose positions together make up four fifths of the reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Oct 21 '26 report. Not a forecast, not advice.
Of the 6 companies Mimedx Group, Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 3841, Surgical & Medical Instruments & Apparatus, from each company's own filings. Largest first.
Mimedx Group, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Surgical & Medical Instruments & Apparatus
High 4.85 at 4:30 pm ET, low 4.63 at 9:30 am ET.
tall tick = annual report · 1 on record
227 managers report a position worth $430.9M between them, and 19 of them hold 80% of it.
MDXG (Mimedx Group, Inc.) has 3 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.